The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index, and 1 are not checked yet.
Triglycerides on the rise: should we swap seats on the seesaw?
Open accessAbstract
For decades, cardiovascular risk attributed to lipids beyond low-density lipoprotein (LDL) has focused appropriately on high-density lipoprotein (HDL). Indubitable observational data show a consistent inverse relationship between baseline HDL-C concentrations and cardiovascular risk. Yet, fidelity as a prospective risk marker does not guaranty that an analyte either lies in a causal pathway for disease, or that its therapeutic manipulation will yield clinical benefits. Indeed, multiple strategies to raise HDL levels therapeutically have thus far failed to forestall events in clinical trials [e.g. currently available fibrates, niacin, and the investigated cholesteryl ester transfer protein (CETP) inhibitors]. We await eagerly with an open mind, however, results from the ongoing outcome trials with two additional CETP inhibitors. We also recognize that steady-state concentrations of HDL-C in plasma likely do not reflect the flux of HDL particles, their potential for mediating reverse cholesterol transport, and other putative functions of HDL subclasses. For example, a large body of in vitro and experimental animal studies indicates that HDL particles may have many beneficial actions beyond reverse cholesterol transport. These putative properties of HDL particles include anti-oxidant and anti-inflammatory effects, attributes not assessed by the simple laboratory measurement of HDL-C. These functional facets of HDL may provide novel targets for therapeutic manipulation in a more subtle fashion in the future. Yet, concordant with the data from clinical intervention trials showing lack of benefit (or even harm) with current approaches to pharmacological boosting of HDL-C, recent genetic studies have also cast doubt on HDL-C as a causal risk factor.1 While HDL-C has stood in the spotlight, centre stage, triglycerides have tarried in the wings as a causal cardiovascular risk factor. Adjustment for HDL-C and for other potential confounders tends to attenuate or nullify the association between triglyceride concentration and prospective cardiovascular risk.2,3 HDL-C and triglyceride concentration in plasma tend to vary inversely, such that high levels of triglycerides associate with low levels of HDL, until recently the presumed causal partner in the pair (Figure 1). Curiously, we generally measure fasting triglycerides, although many spend most of their time in post-prandial in the state, bathing our arteries with triglyceride-rich lipoproteins.4 Yet, current data show that either fasting or fed triglyceride concentrations associate with cardiovascular events.5,6 The high-density lipoprotein/triglyceride seesaw. High-density lipoprotein and triglycerides tend to vary inversely. Traditional thought has focused on the benefits of raising high-density lipoprotein and high-density lipoprotein as a protective factor for atherosclerosis. Triglycerides have received less attention as a causal risk factor as adjustment for high-density lipoprotein attenuates its association with risk. The new clinical and genetic data described in this commentary indicate that triglycerides and specifically the apolipoprotein constituent of many triglyceride-rich lipoproteins, apolipoprotein C3, may actually lie in the causal pathway for atherosclerosis. Thus, contrary to common belief, the current data suggest that we should focus more on triglyceride-rich lipoproteins as a target for cardiovascular risk reduction. Fasting or fed, perhaps adjusting triglycerides for HDL-C, instead of the other way around, has misled us. Have we have collectively chosen a seat on the wrong side of the HDL/triglyceride seesaw? (Figure 1). Recent genetic studies have occasioned a re-examination of triglycerides as a causal cardiovascular risk factor. Contemporary genetic analyses indicate that higher concentrations of triglyceride and remnant lipoproteins contribute directly to the pathogenesis of ischaemic heart disease.7,8 The cholesterol content of remnant particles rather than triglycerides themselves likely comprise the causal moiety contained in this lipoprotein class.9 The actual gene or genes responsible for this association have remained conjectural. One protein associated with triglyceride-rich lipoproteins, apolipoprotein C3 (APOC3), associates with cardiovascular risk. The study of the Amish population in Pennsylvania suggested that carriers of an inactive APOC3 gene have lower triglycerides and lower coronary artery calcium scores than unaffected individuals.10 Two independent large studies recently published in New England Journal of Medicine provide strong evidence for the causal role of APOC3 and triglycerides in atherosclerotic vascular disease.11,12 Exxon sequencing of large cohorts in the USA tracked four loss-of-function variants in APOC3. The individuals with such variants had lower triglyceride concentrations, and correspondingly lower risk of coronary heart disease in validation studies. A parallel study performed in Danish populations t
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical and epidemiological studies have demonstrated that triglyceride (TG) elevation is an independent risk factor for increased cardiovascular (CV) events”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [1]
In the citing paper
“despite potent therapies for lowering low‐density lipoprotein cholesterol (LDL‐C), substantial residual risk remains.1, 2, 3”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [1]
In the citing paper
“However, randomized data from large outcome studies across broad populations regarding pharmacological TG lowering and effect on CV outcomes have been mixed (Table 4).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [1]
In the citing paper
“Epidemiological, biological, and genetic studies have provided robust evidence of a strong association between elevated TG levels and higher rates of CV events.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [1]
In the citing paper
“Despite having a well-controlled low-density lipoprotein cholesterol on statin therapy, patients with elevated triglycerides have significant residual risk for coronary events.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“to attenuate or nullify the association between triglyceride concentration and prospective cardiovascular risk.(2,3) HDL-C and triglycer-”
BackgroundRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716 · cited 1×
“to attenuate or nullify the association between triglyceride concentration and prospective cardiovascular risk.(2,3) HDL-C and triglycer-”
BackgroundVarbo, A., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Circulation · doi:10.1161/circulationaha.113.003008 · Cited by 692
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“of an inactive APOC3 gene have lower triglycerides and lowercoronary artery calcium scores than unaffected individuals.(10) Two independent large studies recently published in New England Journal of Medicine provide strong evidence for the causal role of APOC3 and triglycerides in atherosclerotic vascular disease.”
Cited by
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211
Self-citationThe changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873
Self-citationNordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Metadata
- Authors
- Libby, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Libby, Peter
- ORCID
- Libby, Peter
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-29
- Volume
- 36
- Issue
- 13
- Pages
- 774-776
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC4471442
- OpenAlex
- W2107665972
- Cited by
- 85
- References
- 18
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 7 · 2023: 10 · 2022: 10 · 2021: 14 · 2020: 5 · 2019: 12 · 2018: 6 · 2017: 7 · 2016: 7 · 2015: 4
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Heart Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL080472)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triglycerides, HDL cholesterol, cardiovascular risk, triglyceride-rich lipoproteins, postprandial lipemia, reverse cholesterol transport, HDL subfractions, CETP inhibitors, HDL-raising therapy, triglyceride-lowering therapy, dyslipidemia, cardiovascular outcome trials, nicotinic acid, fibrates
- MeSH terms
- Cardiovascular Diseases, Fasting, Humans, Cholesterol, HDL, Mutation, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triglycerides on the rise: should we swap seats on the seesaw? https://app.cochat.ai/papers/10.1093/eurheartj/ehu500
- The paper
- Libby, P. (2015). Triglycerides on the rise: should we swap seats on the seesaw? European Heart Journal. https://doi.org/10.1093/eurheartj/ehu500
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.